Wearable filtrating artificial kidney device

Abstract

A wearable filtrating artificial kidney device, comprising a transfusion inlet (2), a blood pump (3), an arterial pressure detector (4), a blood filter (7), a venous pressure detector (8) and an air detector (9), wherein the transfusion inlet (2), the blood pump (3), the arterial pressure detector (4), a resin hemoperfusion apparatus (5), an active carbon hemoperfusion apparatus (6), the blood filter (7), the venous pressure detector (8) and the air detector (9) are connected sequentially; a liquid waste outlet of the blood filter (7) is connected with an ultrafiltration control pump (10). Glomerulus filtration can be simulated to achieve the goal of removing toxins and excessive moisture in the blood by virtue of ultrafiltration of the blood filter (7). A dialyzate and a complicated dialyzate circulating device are not used for the device, so that the volume and weight of the device can be reduced greatly, and the device can be worn conveniently. The device is simple in structure, easy in operation and low in cost.

Claims

1. A wearable filtrating artificial kidney device, comprising a blood pipeline, wherein the blood pipeline is sequentially provided with a blood inlet switch (1), a transfusion inlet (2), a blood pump (3), an arterial pressure detector (4), a blood filter (7), a venous pressure detector (8), an air detector (9), and a blood outlet switch (12) in a blood flowing direction; the blood filter (7) includes an inlet, an outlet and a liquid waste outlet, the inlet and the outlet are connected with the blood pipeline, the liquid waste outlet is connected with a liquid waste pipeline on which an ultrafiltration control pump (10) and a liquid waste switch (11) are arranged, the arterial pressure detector (4) and the venous pressure detector (8) are respectively used for detecting the pressure at an inlet end and an outlet end of the blood filter (7), and the air detector (9) is used for detecting the amount of bubbles in the returned blood; a resin hemoperfusion apparatus (5) and an active carbon hemoperfusion apparatus (6) are arranged between the arterial pressure detector (4) and the blood filter (7); the resin hemoperfusion apparatus (5) is internally provided with a urease resin microsphere adsorbent and a 2-microglobulin adsorbent.

2. The wearable flit rating artificial kidney device according to claim 1, wherein the active carbon hemoperfusion apparatus (6) is internally provided with a membrane coated activated carbon adsorbent and/or an endotoxin adsorbent.

3. The wearable filtrating artificial kidney device according to claim 1, wherein the arterial pressure detector (4), the venous pressure detector (8) and the air detector (9) are all provided with alarm units that give an alarm respectively while monitoring the data exceeds a preset threshold, and all detectors are connected with a display.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIG. 1 shows the functional block diagram of the present invention.

(2) In the FIGURE: 1. Blood inlet switch; 2. Transfusion inlet; 3. Blood pump; 4. Arterial pressure detector; 5. Resin hemoperfusion apparatus; 6. Active carbon hemoperfusion apparatus; 7. Blood filter, 8. Venous pressure detector; 9. Air detector; 10. Ultrafiltration control pump; 11. Liquid waste switch; 12. Blood outlet switch.

DETAILED DESCRIPTION OF THE INVENTION

(3) The followings are further descriptions of the present invention with reference to the drawings:

(4) Embodiment 1

(5) Please refer to FIG. 1, a wearable filtrating artificial kidney device comprises a blood pipeline, wherein the blood pipeline is sequentially provided with a blood inlet switch 1, a transfusion inlet 2, a blood pump 3, an arterial pressure detector 4, a blood filter 7, a venous pressure detector 8, an air detector 9, and a blood outlet switch 12 in a blood flowing direction;

(6) the blood filter 7 includes an inlet, an outlet and a liquid waste outlet, wherein the inlet and the outlet are connected with the blood pipeline, the liquid waste outlet is connected with a liquid waste pipeline on which an ultrafiltration control pump 10 and a liquid waste switch 11 are arranged,

(7) the arterial pressure detector 4 and the venous pressure detector 8 are respectively used for detecting pressure at an inlet end and an outlet end of the blood filter 7, and the air detector 9 is used for detecting the amount of bubbles in the returned blood.

(8) In the embodiment: a resin hemoperfusion apparatus 5 and an active carbon hemoperfusion apparatus 6 are arranged between the arterial pressure detector 4 and the blood filter 7; the active carbon hemoperfusion apparatus 6 is internally provided with a membrane coated activated carbon adsorbent and/or an endotoxin adsorbent; the resin hemoperfusion apparatus 5 is internally provided with an urease resin microsphere adsorbent and a 2-microglobulin adsorbent; the arterial pressure detector 4, the venous pressure detector 8 and the bubble detector 9 are all provided with alarm units that give an alarm respectively while monitoring the data exceeds a preset threshold, and all detectors are connected with a display.

(9) According to the present invention, all parts of the wearable filtrating artificial kidney device are miniaturized to facilitate wearing.

(10) A blood inlet switch 1 and a blood outlet switch 12 are connected with blood vessels of a patient by the blood pipeline during treatment, and a diluent can be transfused into the transfusion inlet 2; the blood from the patent and the diluent input into the transfusion inlet 2 are delivered to an arterial pressure detector 4 for pressure detection by the blood pump 3, and then sequentially delivered to the resin hemoperfusion apparatus 5 and the active carbon hemoperfusion apparatus for blood purification; the purified blood is delivered to the blood filter 7 for further purification, and then delivered to a venous pressure detector 8 and an air detector 9 for detecting venous pressure and bubbles respectively, and finally returned to the blood of the patient after being detected to be safe.

(11) Before treatment, the blood inlet switch 1 is closed, and heparin is transfused from the transfusion inlet 2 to realize heparinization of the blood pipeline, remove the bubbles in the blood pipeline, the resin hemoperfusion apparatus 5, the active carbon hemoperfusion apparatus 6 and the blood filter 7; the blood filter 7 and the ultrafiltration control pump 10 are started to filtrate normal saline on a liquid waste switch 11, and washing of the heparin saline is stopped after all bubbles are removed.

(12) During treatment, the two ends of the blood pipelines are connected with the blood of the patient; the blood inlet switch 1 and the blood outlet switch 12 are opened so that a closed blood loop is constituted between the blood pipeline and the human body; the blood sequentially flows through a blood pump 3, the arterial pressure detector 4, the resin hemoperfusion apparatus 5, the active carbon hemoperfusion apparatus 6, the blood filter 7, the venous pressure detector 8 and the air detector 9 sequentially by virtue of the blood pipeline, and then purified by the resin hemoperfusion apparatus 5, the active carbon hemoperfusion apparatus 6 and the blood filter 7; the purified blood is returned to the patient in vivo after the liquid waste is removed from the liquid waste switch 11.

(13) Upon treatment, the blood inlet switch 1 is closed, the normal saline is transfused from the transfusion inlet 2, and then is used for washing continuously and transfused to the patient in vivo; after the liquid waste is not discharged, the blood outlet switch 12 is turned off, and the blood filter 7 and the ultrafiltration control pump 10 are closed.

(14) According to the device provided by the present invention, the blood flow velocity is 60-150 mL/min, the membrane area of the blood filter 7 is 0.6-1.0 m2; the sorting coefficient of a blood filtration membrane to vitamin B12 is 0.9; the retention rate for albumin is not lower than 0.95; the ultrafiltration coefficient is not lower than 200 mL/kPa.Math.h.

(15) The adsorption capacity of resin hemoperfusion apparatus 5 for the 2-microglobulin is not lower than 50 mg, and the decomposition rate for the urea is not lower than 100 mg/h.

(16) The active carbon hemoperfusion apparatus 6 for creatinine has the adsorption capacity for the creatinine of not lower than 250 mg, and also has the acid-base balance.

(17) The clinical pilot experimental results show that the dehydrating amount is 1-3 L, the total amount of 2-microglobulin is reduced by 30%, and the total amount of urea nitrogen is reduced by 30-35%.

(18) What described above are only preferred embodiments of the present invention, which do not make any limitations to the technical scope of the present invention. Therefore, any minor amendments, equivalent alterations and modifications made for the above embodiments according to the technical essence of the present invention are still under the scope of the technical scheme provided by the present invention.